$AIM
AIM ImmunoTech Inc. Stock $aim

$aim Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000149315224045971 Filed on November 14, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$35.00K	$46.00K
YoY Change		-23.91%	119.05%
Cost Of Revenue		$8.000K	$30.00K
YoY Change		-73.33%
Gross Profit		$27.00K	$16.00K
YoY Change		68.75%	-23.81%
Gross Profit Margin		77.14%	34.78%
Selling, General & Admin		$3.210M	$5.439M
YoY Change		-40.98%	5.2%
% of Gross Profit		11888.89%	33993.75%
Research & Development		$1.437M	$2.734M
YoY Change		-47.44%	99.27%
% of Gross Profit		5322.22%	17087.5%
Depreciation & Amortization		$63.00K	$53.00K
YoY Change		18.87%	89.29%
% of Gross Profit		233.33%	331.25%
Operating Expenses		$1.437M	$2.734M
YoY Change		-47.44%	99.27%
Operating Profit		-$4.489M	-$8.157M
YoY Change		-44.97%	25.09%
Interest Expense		$202.0K	-$16.00K
YoY Change		-1362.5%
% of Operating Profit
Other Income/Expense, Net		$718.0K	$294.0K
YoY Change		144.22%	70.93%
Pretax Income		-$3.700M	-$7.816M
YoY Change		-52.66%	22.41%
Income Tax
% Of Pretax Income
Net Earnings		-$3.700M	-$7.816M
YoY Change		-52.66%	22.41%
Net Earnings / Revenue		-10571.43%	-16991.3%
Basic Earnings Per Share		-$0.06	-$0.16
Diluted Earnings Per Share		-$0.06	-$0.16
COMMON SHARES
Basic Shares Outstanding	63.71M shares	57.14M shares	48.67M shares
Diluted Shares Outstanding		57.68M shares	48.64M shares

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.202M	$22.43M
YoY Change	-67.89%	-38.95%
Cash & Equivalents	$915.0K	$15.26M
Short-Term Investments	$6.287M	$7.167M
Other Short-Term Assets	$368.0K	$263.0K
YoY Change	39.92%	-94.03%
Inventory
Prepaid Expenses
Receivables		$48.00K
Other Receivables		$0.00
Total Short-Term Assets	$7.570M	$22.74M
YoY Change	-66.71%	-44.73%
LONG-TERM ASSETS
Property, Plant & Equipment	$117.0K	$136.0K
YoY Change	-13.97%	15.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.716M	$2.102M
YoY Change	29.21%	-1.68%
Total Long-Term Assets	$6.018M	$5.119M
YoY Change	17.56%	-0.31%
TOTAL ASSETS
Total Short-Term Assets	$7.570M	$22.74M
Total Long-Term Assets	$6.018M	$5.119M
Total Assets	$13.59M	$27.86M
YoY Change	-51.23%	-39.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.264M	$2.788M
YoY Change	124.68%	191.33%
Accrued Expenses	$1.011M	$1.721M
YoY Change	-41.26%	-2.6%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.593M
YoY Change
Total Short-Term Liabilities	$10.10M	$4.716M
YoY Change	114.16%	62.9%
LONG-TERM LIABILITIES
Long-Term Debt	$139.0K	$0.00
YoY Change
Other Long-Term Liabilities	$437.0K	$543.0K
YoY Change	-19.52%	-21.87%
Total Long-Term Liabilities	$139.0K	$543.0K
YoY Change	-74.4%	-21.87%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.10M	$4.716M
Total Long-Term Liabilities	$139.0K	$543.0K
Total Liabilities	$10.68M	$5.259M
YoY Change	103.0%	46.49%
SHAREHOLDERS EQUITY
Retained Earnings	-$420.9M	-$396.9M
YoY Change	6.03%	5.52%
Common Stock	$59.00K	$48.00K
YoY Change	22.92%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.912M	$22.60M
YoY Change
Total Liabilities & Shareholders Equity	$13.59M	$27.86M
YoY Change	-51.23%	-39.81%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$3.700M	-$7.816M
YoY Change	-52.66%	22.41%
Depreciation, Depletion And Amortization	$63.00K	$53.00K
YoY Change	18.87%	89.29%
Cash From Operating Activities	-$3.110M	-$5.671M
YoY Change	-45.16%	14.15%
INVESTING ACTIVITIES
Capital Expenditures	$18.00K	$184.0K
YoY Change	-90.22%	-1020.0%
Acquisitions
YoY Change
Other Investing Activities	$352.0K	-$152.0K
YoY Change	-331.58%	-156.3%
Cash From Investing Activities	$334.0K	-$336.0K
YoY Change	-199.4%	-234.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	137.0K	233.0K
YoY Change	-41.2%	832.0%
NET CHANGE
Cash From Operating Activities	-3.110M	-5.671M
Cash From Investing Activities	334.0K	-336.0K
Cash From Financing Activities	137.0K	233.0K
Net Change In Cash	-2.639M	-5.774M
YoY Change	-54.3%	23.03%
FREE CASH FLOW
Cash From Operating Activities	-$3.110M	-$5.671M
Capital Expenditures	$18.00K	$184.0K
Free Cash Flow	-$3.128M	-$5.855M
YoY Change	-46.58%	18.33%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
	us-gaap	Revenues Revenues	125000	usd
	us-gaap	Revenues Revenues	137000	usd
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0000946644
CY2024Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	6287000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	368000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	7570000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	117000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	653000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2532000	usd
CY2024Q3	us-gaap	Assets Assets	13588000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	6264000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1011000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	232000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	10100000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	437000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	10676000	usd
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	59000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-420861000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	2912000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13588000	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent		usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable		usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	AIM	Gain Loss On Warrant Issuance GainLossOnWarrantIssuance		usd
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Entity File Number EntityFileNumber	001-27072
	dei	Entity Registrant Name EntityRegistrantName	AIM IMMUNOTECH INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	52-0845822
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2117 SW Highway 484
	dei	Entity Address City Or Town EntityAddressCityOrTown	Ocala
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	34473
	dei	City Area Code CityAreaCode	(352)
	dei	Local Phone Number LocalPhoneNumber	448-7797
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	AIM
	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	63706446	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	915000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5439000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7631000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1184000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	302000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	14556000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	127000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	697000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2313000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2716000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1688000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1986000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	223000	usd
CY2024Q3	us-gaap	Notes Payable Current NotesPayableCurrent	2593000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8652000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	495000	usd
CY2024Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	139000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	9147000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	35000	usd
CY2024Q3	us-gaap	Revenues Revenues	35000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1437000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3079000	usd
CY2024Q3	us-gaap	Costs And Expenses CostsAndExpenses	4524000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	718000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-3700000	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent		usd
CY2023Q3	us-gaap	Interest Expense InterestExpense		usd
	us-gaap	Interest Expense InterestExpense		usd
CY2024Q3	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2023Q3	AIM	Gain Loss On Warrant Issuance GainLossOnWarrantIssuance		usd
	AIM	Gain Loss On Warrant Issuance GainLossOnWarrantIssuance		usd
CY2024Q3	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss		usd
	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss		usd
CY2024Q1	AIM	Stock Issued During Period Value Cashless Exercise Of Warrants StockIssuedDuringPeriodValueCashlessExerciseOfWarrants		usd
CY2024Q1	AIM	Stock Issued During Period Value Committed Shares StockIssuedDuringPeriodValueCommittedShares		usd
CY2024Q2	AIM	Stock Issued During Period Value Preferred Shares Expired StockIssuedDuringPeriodValuePreferredSharesExpired		usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts		usd
CY2024Q3	AIM	Stock Issued During Period Value Preferred Shares Expired StockIssuedDuringPeriodValuePreferredSharesExpired		usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss		usd
	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives		usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts		usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables		usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets		usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
	AIM	Proceeds From Issuance Of Equity Warrants ProceedsFromIssuanceOfEquityWarrants		usd
	AIM	Conversion Of Series B Preferred ConversionOfSeriesBPreferred		usd
	AIM	Conversion Of Note Payable Interest Into Shares ConversionOfNotePayableInterestIntoShares		usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent		usd
CY2024Q3	AIM	Lessee Operating Lease Liability Payments Due After Year Three LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
CY2023Q4	us-gaap	Assets Assets	19381000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6443000	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	58668647	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	58668647	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49102484	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49102484	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	49000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	423714000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	419004000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-409508000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	10234000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19381000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	46000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	125000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	137000	usd
CY2023Q3	us-gaap	Revenues Revenues	46000	usd
CY2024Q3	us-gaap	Manufacturing Costs ManufacturingCosts	8000	usd
CY2023Q3	us-gaap	Manufacturing Costs ManufacturingCosts	30000	usd
	us-gaap	Manufacturing Costs ManufacturingCosts	24000	usd
	us-gaap	Manufacturing Costs ManufacturingCosts	30000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2734000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4533000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7739000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5439000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9485000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10280000	usd
CY2023Q3	us-gaap	Costs And Expenses CostsAndExpenses	8203000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	14042000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	18049000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4489000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8157000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13917000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17912000	usd
CY2024Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	273000	usd
CY2023Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	-310000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	96000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-201000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	294000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3379000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	811000	usd
CY2024Q3	us-gaap	Interest Expense InterestExpense	202000	usd
	us-gaap	Interest Expense InterestExpense	453000	usd
CY2023Q3	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	39000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	16000	usd
	AIM	Gain Loss On Warrant Issuance GainLossOnWarrantIssuance	-458000	usd
CY2023Q3	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss	-318000	usd
	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss	-900000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-7816000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11353000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16386000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57677016	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57677016	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48635165	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48635165	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53351467	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53351467	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48483802	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48483802	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	10234000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	329000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	80000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5817000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	4826000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	532000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	2500000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	80000	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1836000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	6102000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	180000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	330000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3700000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	2912000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	38468000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	100000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	82000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3661000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	34989000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	50000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4909000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	30135000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	30135000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	233000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	50000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7816000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	22602000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	22602000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11353000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16386000	usd
	us-gaap	Depreciation Depreciation	28000	usd
	us-gaap	Depreciation Depreciation	30000	usd
	AIM	Abandonment Of Patent And Trademark Rights AbandonmentOfPatentAndTrademarkRights	46000	usd
	AIM	Abandonment Of Patent And Trademark Rights AbandonmentOfPatentAndTrademarkRights	14000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	154000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	150000	usd
	AIM	Changes In Rou Assets ChangesInRouAssets	226000	usd
	AIM	Changes In Rou Assets ChangesInRouAssets	151000	usd
	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss	-900000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	490000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	182000	usd
	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	95000	usd
	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	-201000	usd
	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	-458000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	232000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	9000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1181000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1676000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	63000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-192000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-231000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-136000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1028000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-179000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2411000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-799000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	915000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10933000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11509000	usd
	us-gaap	Proceeds From Sale Of Investment Projects ProceedsFromSaleOfInvestmentProjects	1597000	usd
	us-gaap	Proceeds From Sale Of Investment Projects ProceedsFromSaleOfInvestmentProjects	924000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	158000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	1155000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	419000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	377000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1002000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-618000	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	860000	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	338000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	2500000	usd
	AIM	Proceeds From Issuance Of Equity Warrants ProceedsFromIssuanceOfEquityWarrants	2047000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5407000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	338000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4524000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11789000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5439000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27053000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	915000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	15264000	usd
	AIM	Operating Leaseright Of Use Assets OperatingLeaserightOfUseAssets	-3000	usd
	AIM	Operating Leaseright Of Use Assets OperatingLeaserightOfUseAssets	49000	usd
	AIM	Unrealized Gain Loss On Marketable Investments UnrealizedGainLossOnMarketableInvestments	373000	usd
	AIM	Unrealized Gain Loss On Marketable Investments UnrealizedGainLossOnMarketableInvestments	-71000	usd
	AIM	Conversion Of Series B Preferred ConversionOfSeriesBPreferred	6000	usd
	AIM	Conversion Of Note Payable Interest Into Shares ConversionOfNotePayableInterestIntoShares	175000	usd
CY2024Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024Q3	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	6287000	usd
CY2023Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	7631000	usd
CY2024Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	6287000	usd
	us-gaap	Debt Instrument Convertible Type Of Equity Security DebtInstrumentConvertibleTypeOfEquitySecurity	The net gain recognized for the three-month period ended September 30, 2024 on equity securities was $273,000. The net losses recognized for the three-month period ended September 30, 2024 on equity securities sold during the period were ($59,000). The unrealized gains recognized for the three-month period ended September 30, 2024 on equity securities still held was $332,000. The net gain recognized for the nine-month period ended September 30, 2024 on equity securities was $96,000. The net losses recognized for the nine-month period ended September 30, 2024 on equity securities sold during the period were ($277,000). The unrealized gains recognized for the nine-month period ended September 30, 2024 on equity securities still held was $373,000.
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7631000	usd
CY2023	us-gaap	Debt Instrument Convertible Type Of Equity Security DebtInstrumentConvertibleTypeOfEquitySecurity	The net loss recognized for the three-month period ended September 30, 2023 on equity securities was ($309,000). The net losses recognized for the three-month period ended September 30, 2023 on equity securities sold during the period were ($42,000). The unrealized losses recognized during the three-month period ended September 30, 2023 on equity securities still held was ($267,000). The net losses recognized for the nine-month period ended September 30, 2023 on equity securities was ($201,000). The net losses recognized for the nine-month period ended September 30, 2023 on equity securities sold during the period were ($130,000). The unrealized losses recognized during the nine-month period ended September 30, 2023 on equity securities still held was ($71,000).
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1466000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1448000	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1349000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1321000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	117000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	127000	usd
	us-gaap	Depreciation Depreciation	28000	usd
	us-gaap	Depreciation Depreciation	30000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3547000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-1015000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2532000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3176000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-863000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2313000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2313000	usd
	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	419000	usd
	AIM	Finitelived Intangible Assets Abandonments FinitelivedIntangibleAssetsAbandonments	46000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	154000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2532000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	72000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	268000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	265000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	239000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	219000	usd
CY2024Q3	AIM	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	1469000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2532000	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	414000	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	790000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1352000	usd
CY2024Q3	AIM	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	132000	usd
CY2023Q4	AIM	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	184000	usd
CY2024Q3	us-gaap	Interest Payable Current InterestPayableCurrent	51000	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	37000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	36000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1011000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1986000	usd
CY2023Q4	us-gaap	Unsecured Debt UnsecuredDebt	0	usd
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	3301000	usd
CY2024Q3	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	-555000	usd
CY2024Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	14000	usd
CY2024Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	2732000	usd
CY2024Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	2593000	usd
CY2024Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	139000	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	226000	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	232000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	226000	usd
	us-gaap	Loan Processing Fee LoanProcessingFee	6000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	750000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	2551000	usd
CY2024Q3	us-gaap	Deferred Finance Costs Current Gross DeferredFinanceCostsCurrentGross	3000000	usd
CY2024Q3	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	397000	usd
CY2024Q3	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	10000	usd
CY2024Q3	us-gaap	Deferred Finance Costs Noncurrent Gross DeferredFinanceCostsNoncurrentGross	301000	usd
CY2024Q3	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	159000	usd
CY2024Q3	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	3000	usd
CY2018	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	(27,028 options post reverse split)
CY2019	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	one year (39,266 options post reverse split).
CY2024Q3	us-gaap	Share Based Compensation ShareBasedCompensation	80000	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	50000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	490000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	182000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	250000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	250000	usd
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	53400	usd
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	35000	usd
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2024Q3	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	0.20
CY2024Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	114	shares
CY2024Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	8.80
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2024Q3	AIM	Common Stock Shares With Limitations And Restrictions On Usage CommonStockSharesWithLimitationsAndRestrictionsOnUsage	8000000	shares
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	58668647	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	58668647	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49102484	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49102484	shares
CY2020Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	264000	usd
CY2020Q1	AIM	Warrant Modifications WarrantModifications	46000	usd
CY2024Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	152160	shares
CY2024Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	2500000	usd
CY2024Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	205000	shares
CY2024Q1	AIM	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Expired ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantExpired	5830028	shares
	AIM	Low Range Of Probability LowRangeOfProbability	0.005	pure
	AIM	Medium Range Of Probability MediumRangeOfProbability	0.010	pure
	AIM	High Range Of Probability HighRangeOfProbability	0.050	pure
	AIM	High Range Of Probability HighRangeOfProbability	0.050	pure
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	653000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	697000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	669000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	718000	usd
CY2024Q3	AIM	Operation Lease Right Of Use Asset Accumulated Amortization OperationLeaseRightOfUseAssetAccumulatedAmortization	404000	usd
CY2023Q4	AIM	Operation Lease Right Of Use Asset Accumulated Amortization OperationLeaseRightOfUseAssetAccumulatedAmortization	363000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	226000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	214000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	205000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	253000	usd
	us-gaap	Lease Cost LeaseCost	431000	usd
	us-gaap	Lease Cost LeaseCost	467000	usd
	us-gaap	Lease Cost LeaseCost	431000	usd
	us-gaap	Lease Cost LeaseCost	467000	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P32M
CY2023Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P41M
CY2024Q3	us-gaap	Debt Weighted Average Interest Rate DebtWeightedAverageInterestRate	0.102	pure
CY2023Q4	us-gaap	Debt Weighted Average Interest Rate DebtWeightedAverageInterestRate	0.10	pure
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	78000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	276000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	244000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	159000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	88000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	669000	usd

Files In Submission

Name	View Source	Status
0001493152-24-045971-index-headers.html	Edgar Link	pending
0001493152-24-045971-index.html	Edgar Link	pending
0001493152-24-045971.txt	Edgar Link	pending
0001493152-24-045971-xbrl.zip	Edgar Link	pending
aim-20240930.xsd	Edgar Link	pending
ex-a_001.jpg	Edgar Link	pending
ex-a_002.jpg	Edgar Link	pending
ex-a_003.jpg	Edgar Link	pending
ex-a_004.jpg	Edgar Link	pending
ex-a_005.jpg	Edgar Link	pending
ex-a_006.jpg	Edgar Link	pending
ex-a_007.jpg	Edgar Link	pending
ex-a_008.jpg	Edgar Link	pending
ex-a_009.jpg	Edgar Link	pending
ex-a_010.jpg	Edgar Link	pending
aim-20240930_cal.xml	Edgar Link	unprocessable
aim-20240930_def.xml	Edgar Link	unprocessable
aim-20240930_lab.xml	Edgar Link	unprocessable
aim-20240930_pre.xml	Edgar Link	unprocessable
ex-a_048.jpg	Edgar Link	pending
ex-a_049.jpg	Edgar Link	pending
ex-a_050.jpg	Edgar Link	pending
ex-a_055.jpg	Edgar Link	pending
ex-a_056.jpg	Edgar Link	pending
ex10-15.htm	Edgar Link	pending
ex3-1i1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-1.htm	Edgar Link	pending
ex4-1_001.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
image_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AIM
AIM ImmunoTech Inc. Stock $aim

2024 Q4 Form 10-Q Financial Statement

#000149315224045971 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AIM AIM ImmunoTech Inc. Stock $aim

2024 Q4 Form 10-Q Financial Statement

#000149315224045971 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AIM
AIM ImmunoTech Inc. Stock $aim